Labcorp Holdings Inc. (LH)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $30.08B
Last updated: Nov 17, 2026 at 11:06 AM ET
Labcorp Holdings Inc. (LH) P/E Ratio & Valuation History
Labcorp Holdings (LH) trades at 20.6x trailing earnings and 2.1x sales. Its P/E of 20.6x is above its 5-year median of 15.3x. Its forward P/E is 20.0x. The median P/E across 11 similar companies is 31.5x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 3.0% higher over the next year. Its free cash flow yield is 4.3%.
| Multiple | Value |
|---|---|
| P/E (trailing) | 20.6x |
| Forward P/E | 20.0x |
| Price to sales | 2.1x |
| Price to book | 3.4x |
| EV/EBITDA | 17.7x |
| Price to FCF | 23.5x |
| EV/FCF | 27.8x |
| PEG | 1.6 |
| FCF yield | 4.3% |
Historical Medians
Against its 10-year medians, its P/E is 34.6% above 15.3x, its P/S is 31.3% above 1.6x and its P/B is 41.7% above 2.4x.
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/E | 20.6x | 15.3x | 15.3x |
| P/S | 2.1x | 1.6x | 1.6x |
| P/B | 3.4x | 2.4x | 2.4x |
Valuation History
Over the 10 year ends shown, its P/E ranged from 8.5x in 2020 to 16.6x in 2017.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $250.88 | 15.3x | 1.5x | 2.4x |
| 2024 | $229.32 | 15.7x | 1.5x | 2.4x |
| 2023 | $227.29 | 16.3x | 1.6x | 2.5x |
| 2022 | $235.48 | 11.8x | 1.8x | 2.1x |
| 2021 | $314.21 | 11.0x | 2.3x | 2.9x |
| 2020 | $203.55 | 8.5x | 1.4x | 2.1x |
| 2019 | $169.17 | 15.0x | 1.4x | 2.2x |
| 2018 | $126.36 | 11.5x | 1.1x | 1.8x |
| 2017 | $159.51 | 16.6x | 1.6x | 2.4x |
| 2016 | $128.38 | 14.7x | 1.4x | 2.5x |
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About LH
What is LH's forward P/E ratio?
Labcorp Holdings has a forward P/E ratio of 20.0x.
Is LH stock overvalued?
GNG's valuation label for LH is Fairly valued. Its P/E of 20.6x compares with a median of 31.5x across 11 similar companies.
What is LH's price to sales ratio?
Labcorp Holdings has a price to sales ratio of 2.1x.
What is Labcorp Holdings's average P/E ratio over 5 years?
Labcorp Holdings's median P/E over the last 5 years is 15.3x, from 60 month-end values through Oct 2026.
What is LH's PEG ratio?
Labcorp Holdings has a PEG ratio of 1.6.
LH pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts